Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

ales) adjustment in respect of inventories acquired through the acquisition of Transkaryotic Therapies Inc. ("TKT"). Excluding the impact of this fair value adjustment, cost of sales as a percentage of product sales in 2006 was 13% in 2006. The increase in cost of sales as a percentage of product sales in 2007 over 2006 was primarily due to a shift in product mix resulting from increased sales of launched products, which had lower margins than existing products, and the write-off of inventory following the voluntary market withdrawal of a limited quantity of DAYTRANA patches.

For the year to December 31, 2007 cost of sales included a charge of US$5.3 million for share based compensation (2006: US$2.0 million) which included a US$2.1 million cumulative catch up charge (2006: US$nil) in respect of the 2005 option awards, for further information see SG&A below.

Research and development (R&D)

R&D expenditure increased to US$775.2 million for the year to December 31, 2007 (36% of product sales), up from US$295.8 million in the year to December 31, 2006 (19% of product sales).

The increase in R&D expenditure during the year to December 31, 2007 primarily relates to the following:

(i) a non-cash charge of US$100.0 million recognised on the effective settlement of Shire's pre-existing relationship with New River Pharmaceuticals Inc. ("New River"). This charge represents the write-off of capitalised up-front and milestone payments made by Shire prior to the acquisition of New River. This charge is presented within R&D as at the time of the New River acquisition VYVANSE, although approved by the FDA, had not yet received the final scheduling classification from the Drug Enforcement Agency ("DEA") and was therefore not available for commercial sale. Further details in respect of this charge are included in Note 3 of the Financial Statements; and

(ii) an intangible asset impairment charge for the year to December 31, 2007 of US$256.4 mi
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 Dr. Jason Wendel – recipient of ... one of the Top 10 Plastic Surgeon Specialists for Nashville, ... products. His complete line includes a Hydration Booster, Retexturing Night ... face and skin a younger, more radiant appearance while protecting ... is different, that is why at Dr. J. J. Wendel ...
(Date:7/28/2014)... 2014 Sapphire Energy, Inc. , a ... appointment of biotechnology veteran James Levine as ... Levine replaces Cynthia ,CJ, Warner, who is stepping down ... of the company,s board of directors. "The ... deliver commercial scale algae-based fuels has been tremendous, from ...
(Date:7/28/2014)... Research and Markets has announced ... 2014-2018" report to their offering. ... biology covers the designing and engineering of completely new ... redesigning of natural biological systems that provide improved and ... of extreme genetic engineering because it not only alters ...
(Date:7/28/2014)... , July 28, 2014   Propeller Health , ... announced the hire of Brad Towle as ... be responsible for driving the company,s sales growth, customer ... in healthcare, and specifically his past role in the ... the company at this pivotal time in the industry," ...
Breaking Biology Technology:Dr. J. J. Wendel Launches New Line of Skin Care Products 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3Global Synthetic Biology Market 2014-2018 2Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2
... Md., June 12 /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: ... international,healthcare services and Western healthcare products in the ... to charges in,the fourth quarter which will be ... which will be filed with the Securities and ...
... Supports Development of Strong Scientific Capacity in Latin,America, ... and the University of California at San Francisco ... been named 2008 Pew,Latin American Fellows in the ... UCSF, the highly competitive fellowship program offers talented,young ...
... The new Pearl(TM) In Vivo,Imaging System for ... (NIR) results in less than 30 seconds. The ... Infrared Dyes, the proven performers,for NIR imaging at ... are acquired in 30 seconds," says,Jeff Harford, LI-COR ...
Cached Biology Technology:Chindex International, Inc. Quantifies Fourth Quarter Charges 2Chindex International, Inc. Quantifies Fourth Quarter Charges 3Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences 2LI-COR Biosciences Introduces Near-Infrared Small Animal Imager 2
(Date:7/29/2014)... San Francisco is the first to show that while ... cellular aging, these negative effects may be reduced by ... , "The study participants who exercised, slept well and ... who didn,t maintain healthy lifestyles, even when they had ... PhD, assistant professor in the department of psychiatry at ...
(Date:7/28/2014)... a circulatory problem of the legs called peripheral vascular ... surgery in serious cases. This disease can lead to ... , At The University of Texas Health Science Center ... preventative treatment in a mouse model of the disease ... Their proof-of-concept study appears in the journal Cell ...
(Date:7/28/2014)... The genome of Solanum pennellii , a wild ... an international group of researchers including the labs headed ... UC Davis Department of Plant Biology. The new genome ... , The work, published July 27 in the journal ... and colleagues at Aachen University in Germany. The UC ...
Breaking Biology News(10 mins):Healthy lifestyle may buffer against stress-related cell aging, study says 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2
... human DNA is the genetic equivalent of e-mail spam: short ... more of themselves. After starting out in our primate ... called an Alu retrotransposon now takes up 10 percent of ... newborn baby has a new Alu retrotransposon somewhere in its ...
... of how neurons and muscle cells establish lifelong communication ... may be mutated and/or attacked in muscular dystrophy. ... direct construction of the nerve-muscle contact or synapse. MuSK ... talk so synpases can form and receptors that enable ...
... are exposed to a wide range of environmental threats ... life, throughout their youth and into adulthood. Writing in ... Environmental Health scientists from the World Health Organization ... both industrialized and developing countries to assess the environmental ...
Cached Biology News:Mapping a clan of mobile selfish genes 2Mapping a clan of mobile selfish genes 3Mediator in communication between neurons and muscle cells found 2Childhood environmental health 2
Unit Definition: 1 U corresponds to the amount of enzyme which produces 1 mol protons per minute at pH 5.5 and 30C (peptin from citrus peel, Fluka-No. 76280, as substrate)...
Recorder, 6", 7 Day, 1 Pen, 0 to 100°C, 220V, 50/60 Hz, for 4520, Customer Installed...
... systems provide linking and labelling reagents ... specific primary antibodies for visualising cellular ... accomplished using an ultra-sensitive indirect labelling ... technology. Secondary antibodies are polymerised directly ...
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
Biology Products: